Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma

被引：0
|
作者：
Liu, Jiajian
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2663
引用
收藏
页数：1
相关论文
共 50 条
  • [21] CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients
    Mohammadzadeh, Adel
    Rad, Isa Abdi
    Ahmadi-Salmasi, Babak
    JOURNAL OF NEUROIMMUNOLOGY, 2018, 323 : 105 - 108
  • [22] Tim-3 and PD-1 are differently expressed on exhausted T cells in HIV infected patients
    Grabmeier-Pfistershammer, K.
    Leitner, J.
    Rieger, A.
    Steinberger, P.
    IMMUNOLOGY, 2012, 137 : 208 - 208
  • [23] PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE CLEVER-1 ANTIBODY BEXMARILIMAB IN COMBINATION WITH PD-1 BLOCKADE IN PATIENTS WITH ADVANCED SOLID TUMORS - BEXCOMBO
    Bono, Petri
    Jalkanen, Juho
    Pawlitzky, Inka
    Fjaellskog, Marie-Louise
    Ahlin, Cecilia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A742 - A742
  • [24] PHASE I STUDY OF ONO-4538 (BMS-936558), AN ANTI PD-1 ANTIBODY, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Yamamoto, N.
    Yamada, Y.
    Nokihara, H.
    Asahina, H.
    Shibata, T.
    Tamura, Y.
    Seki, Y.
    Honda, K.
    Tanabe, Y.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 159 - 159
  • [25] The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study
    Ruan, Dan-Yun
    Wei, Xiao-Li
    Liu, Fu-Rong
    Hu, Xi-Chun
    Zhang, Jian
    Ji, Dong-Mei
    Huang, Ding-Zhi
    Zhao, Yan-Qiu
    Pan, Hong-Min
    Liao, Wang-Jun
    Yang, Kun-Yu
    Xu, Nong
    Lu, Xiao-Xiao
    Chen, Yu-Ling
    Zhang, Wen
    Zhou, Hui
    Zhao, Hong-Yun
    Xu, Rui-Hua
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [26] PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors
    Wang, Jaeyun Jane
    Burger, Peter
    Taube, Janis
    Soni, Abha
    Chaichana, Kaisorn
    Sheu, Mary
    Belcaid, Zineb
    Jackson, Christopher
    Lim, Michael
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (12)
  • [27] Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)
    Falchook, Gerald Steven
    Ribas, Antoni
    Davar, Diwakar
    Eroglu, Zeynep
    Wang, Judy S.
    Luke, Jason J.
    Hamilton, Erika P.
    Di Pace, Brian
    Wang, Tianli
    Ghosh, Srimoyee
    Dhar, Arindam
    Borgovan, Theo
    Waszak, Angela
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Bispecific anti-PD-L1/PD-1 antibodies for advanced solid tumors: a patent evaluation of US2019010232
    Villa-Ruano, Nemesio
    Guerrero-Gonzalez, Tayde
    Gomez-Conde, Eduardo
    Perez-Santos, Martin
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2020, 30 (10) : 723 - 727
  • [29] A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma
    Lin, Tongyu
    Liu, Bin
    Pu, Xingxiang
    Wu, Lin
    Du, Xiaobo
    Mo, Ning
    Song, Zhengbo
    Zhou, Liwei
    Duan, Xianlin
    Zhu, Yanan
    Kang, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Preliminary safety and pharmacodynamic (PD) activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in a phase I dose escalation study of patients with selected advanced solid tumors.
    Hickingbottom, Barbara
    Clynes, Raphael
    Desjarlais, John
    Li, Caiyan
    Ding, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345